Drug Profile
Travoprost extended release - Envisia Therapeutics
Alternative Names: ENV-515Latest Information Update: 22 Mar 2019
Price :
$50
*
At a glance
- Originator Liquidia Technologies
- Developer Envisia Therapeutics
- Class Antiglaucomas; Eye disorder therapies; Prostaglandins; Small molecules
- Mechanism of Action Prostaglandin F2 alpha agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Glaucoma